VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MDAISpectral AI, Inc.
$1.71$54M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksMDAIFinancials

Spectral AI, Inc. (MDAI) Financials

5Y historyFree accessUpdated daily

Operating performance remains severely strained, evidenced by a negative operating margin of 49.4% in 2026Q1 as SG&A expenses continue to outpace gross profit generation.

MDAI Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21
Sales/Revenue16.7M19.65M29.58M18.06M25.37M15.24M
Revenue Growth %-44.27%-33.57%63.83%-28.82%66.47%-
Cost of Goods Sold9.23M10.72M16.31M10.18M14.53M8.19M
COGS % of Revenue-54.58%55.13%56.36%57.28%53.72%
Gross Profit7.47M8.93M13.27M7.88M10.84M7.05M
Gross Margin %44.73%45.42%44.87%43.64%42.72%46.28%
Gross Profit Growth %--32.76%68.45%-27.29%53.67%-
Operating Expenses17.38M17.53M19.86M20.86M13.48M11.23M
OpEx % of Revenue-89.2%67.12%115.55%53.15%73.7%
Selling, General & Admin17.66M17.53M19.86M20.86M13.48M11.23M
SG&A % of Revenue-89.2%67.12%115.55%53.15%73.7%
Research & Development7.09M19.65M29.58M000
R&D % of Revenue-100%100%---
Other Operating Expenses-2M-19.65M-29.58M000
Operating Income-9.92M-8.6M-6.58M-12.98M-2.65M-4.18M
Operating Margin %-59.39%-43.78%-22.25%-71.91%-10.43%-27.42%
Operating Income Growth %--30.7%49.31%-390.52%36.66%-
EBITDA-9.7M-7.97M-5.99M-12.26M-2.08M-4.18M
EBITDA Margin %-58.09%-40.55%-20.26%-67.91%-8.2%-27.42%
EBITDA Growth %-92.78%-32.93%51.12%-489.8%50.24%-
D&A (Non-Cash Add-back)217K635K588K722K568K1K
EBIT-9.82M-8.6M-12.08M-20.84M-2.65M-4.18M
Net Interest Income-1.79M-2.39M-2.95M172K21K0
Interest Income-547K-886K14K172K21K0
Interest Expense1.25M1.51M2.96M000
Other Income/Expense-4.44M1.04M-8.46M-7.86M-159K93K
Pretax Income-14.36M-7.56M-15.04M-20.84M-2.81M-4.09M
Pretax Margin %-85.99%-38.47%-50.86%-115.44%-11.06%-26.81%
Income Tax-48K11K271K11K106K-98K
Effective Tax Rate %0.33%-0.15%-1.8%-0.05%-3.78%2.4%
Net Income-14.29M-7.57M-15.31M-20.85M-2.91M-3.99M
Net Margin %-85.58%-38.53%-51.77%-115.5%-11.48%-26.17%
Net Income Growth %-55.11%50.56%26.56%-616.14%26.98%-
Net Income (Continuing)-14.31M-7.57M-15.31M-20.85M-2.91M-3.99M
Discontinued Operations000000
Minority Interest000000
EPS (Diluted)-0.45-0.29-0.85-1.48-0.16-0.33
EPS Growth %2.81%65.88%42.57%-825%51.52%-
EPS (Basic)--0.29-0.85-1.48-0.16-0.33
Diluted Shares Outstanding31.76M26.52M17.93M14.09M17.88M17.88M
Basic Shares Outstanding31.76M26.52M17.93M14.09M17.88M17.88M
Dividend Payout Ratio------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

BARDA funding dependency risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Contraction Reflects Milestone Lulls

As reported in financial statements, Spectral AI's revenue has experienced a significant downturn, with the most recent quarterly figures showing a 40.5% year-over-year decline, highlighting the inherent volatility of a business model heavily reliant on the timing of government-funded research milestones rather than consistent commercial product sales.

The sharp revenue decline suggests that the company is currently between major phases of its BARDA contracts, which creates artificial lulls in top-line performance. Investors should monitor whether the company can successfully transition from these project-based government inflows to a sustainable commercial revenue stream, as the current trajectory indicates a lack of organic growth durability.

Hardware Costs Constrain Margin Potential

Based on reported figures, Spectral AI maintains a gross margin of approximately 45.4%, a level that appears structurally limited by the manufacturing requirements of its DeepView hardware carts and the absence of a high-margin, recurring software-as-a-service revenue component at this early stage of commercialization.

The current margin profile suggests that the company is struggling to achieve the economies of scale necessary to offset the costs of its specialized imaging hardware. Without a shift toward a higher-margin diagnostic fee model, the company may remain trapped in a low-margin hardware manufacturing cycle that is difficult to scale profitably.

Operating Leverage Remains Severely Strained

According to recent SEC filings, Spectral AI's operating losses remain persistent, with the company reporting a negative operating margin of 49.4% in the most recent quarter, indicating that SG&A expenses continue to outpace the company's ability to generate meaningful gross profit from its current revenue base.

The inability to scale operating income faster than gross profit suggests that the company's overhead, particularly in R&D and clinical trial infrastructure, is currently too heavy for its revenue volume. This lack of operating leverage implies that the company is still in a high-burn development phase, necessitating further capital to sustain its current operational footprint.

Commercialization Hurdles Threaten Long-term Viability

As indicated by the company's financial history, the reliance on non-dilutive government funding masks the underlying risk that the DeepView platform may face significant adoption barriers, including the lack of specific CPT reimbursement codes and the inherent friction of hospital procurement cycles for new medical hardware.

Short-sellers would likely focus on the company's inability to generate positive cash flow outside of government grants, which may suggest that the commercial market for MSI-based wound assessment is not yet ready for adoption. The risk remains that the company's technology may be technically superior but commercially unviable without a fundamental change in the reimbursement landscape.

MDAI — Frequently Asked Questions

Quick answers to the most common questions about buying MDAI stock.

What was Spectral AI, Inc.'s (MDAI) revenue in 2025?

For fiscal year 2025, Spectral AI, Inc. (MDAI) reported total revenue of $19.6M. This represents a 28.9% increase compared to $15.2M in 2021.

Is Spectral AI, Inc. (MDAI) profitable?

Spectral AI, Inc. (MDAI) reported a net loss of $7.6M for the fiscal year ending 2025.

What is Spectral AI, Inc.'s operating profit margin?

Spectral AI, Inc. (MDAI) reported an operating income of $-8.6M, resulting in an operating profit margin of -43.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Spectral AI, Inc.'s gross profit and gross margin?

Spectral AI, Inc. (MDAI) generated $8.9M in gross profit for the year, representing a gross profit margin of 45.4%. This demonstrates the company's core pricing power and production efficiency.